Novasenta develops immunotherapy treatments that leverage the interaction between cancer and the immune system to target and eliminate tumor cells. This approach aims to improve patient outcomes by enhancing the body’s natural defenses against cancer.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer cells exploit interactions with the immune system to evade detection and destruction, hindering the effectiveness of traditional cancer therapies. This immune evasion allows tumors to grow and metastasize, leading to poor patient outcomes.
Solution
Novasenta develops novel immunotherapy treatments that target the specific interactions between cancer cells and the immune system. By selectively modulating these interactions, Novasenta's therapies aim to disrupt the tumor's ability to suppress the immune response, thereby enabling the body's natural defenses to recognize and eliminate cancer cells. This approach seeks to enhance the efficacy of cancer treatment by restoring and amplifying the immune system's anti-tumor activity.
Target Audience
The primary target audience includes patients with advanced cancers who are not responding to conventional therapies, as well as oncologists and researchers seeking innovative immunotherapy approaches.
Features
- Focus on modulating the tumor microenvironment to enhance immune cell infiltration and activity.
- Development of targeted therapies that disrupt specific immune checkpoints exploited by cancer cells.
- Preclinical research evaluating novel immunotherapy combinations for synergistic anti-tumor effects.